Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Position Increased by Shell Asset Management Co.

Shell Asset Management Co. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) by 42.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,460 shares of the biopharmaceutical company’s stock after buying an additional 3,422 shares during the quarter. Shell Asset Management Co.’s holdings in Halozyme Therapeutics were worth $504,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Horizon Advisors Inc. grew its holdings in shares of Halozyme Therapeutics by 188.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 472 shares during the last quarter. Meeder Asset Management Inc. increased its stake in Halozyme Therapeutics by 223.6% in the 2nd quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 512 shares in the last quarter. San Luis Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics during the 1st quarter worth about $36,000. Selective Wealth Management Inc. purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $44,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter worth about $50,000. 91.72% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $53.27 on Thursday. The company has a debt-to-equity ratio of 15.37, a current ratio of 5.97 and a quick ratio of 5.03. Halozyme Therapeutics, Inc. has a one year low of $31.36 and a one year high of $54.88. The business’s 50-day moving average price is $44.27 and its two-hundred day moving average price is $44.55. The company has a market capitalization of $7.20 billion, a P/E ratio of 35.75, a price-to-earnings-growth ratio of 0.96 and a beta of 1.22.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $54.13, for a total transaction of $541,300.00. Following the transaction, the senior vice president now owns 163,137 shares in the company, valued at approximately $8,830,605.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $53.81, for a total value of $269,050.00. Following the completion of the sale, the chief financial officer now directly owns 4,045 shares in the company, valued at $217,661.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $54.13, for a total transaction of $541,300.00. Following the sale, the senior vice president now directly owns 163,137 shares of the company’s stock, valued at $8,830,605.81. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent analyst reports. SVB Leerink boosted their price target on shares of Halozyme Therapeutics from $52.00 to $62.00 and gave the company an “outperform” rating in a report on Monday. StockNews.com initiated coverage on Halozyme Therapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. JMP Securities upped their price target on Halozyme Therapeutics from $60.00 to $62.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 9th. Finally, Morgan Stanley initiated coverage on Halozyme Therapeutics in a research note on Friday, September 9th. They issued an “overweight” rating and a $50.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.57.

Halozyme Therapeutics Company Profile

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.